Study: Increased vision impairment reports linked to semaglutide: analysis of FDA adverse ... as data for the obesity-specific formulation Wegovy were limited. Rapid weight loss (>10% body weight ...

Novo Nordisk filed for approval of an oral, 25-mg formulation of its weight loss blockbuster “earlier this year,” according ...

Drugmaker Eli Lilly said that in Phase 3 studies of over 550 adults, their oral GLP-1 pill, orforglipron, could reduce ...

Hims & Hers stock has dropped over 60% from its peak due to concerns about its GLP-1 business. Read why I think HIMS stock is ...

Potential high value and de-risked development pathway: Existing human safety and tolerability data from ... and semaglutide were equally effective in promoting body weight loss and improving ...

Despite the decision being a win for Novo Nordisk, the compounded drugs sector is far too complex for this to be a final ...

The latest clinical data shared by Lilly indicated a mean weight loss of 20.2% ... last year, the FDA declared a global shortage of both tirzepatide and semaglutide, meaning that compounded ...

Opaganib and semaglutide were equally effective in promoting body weight loss and improving glucose ... Being host-targeted, and based on data accumulated to date, opaganib is expected to maintain ...

New data suggests that the benefits of Novo Nordisk’s GLP-1 agonist semaglutide in preventing cardiovascular diseases may not simply be a result of weight loss ... the FDA approval of Novo ...

Novo Nordisk (NYSE: NVO) stock hit an all-time high of $148.15 in June 2024, marking a remarkable fivefold surge since 2019.

In individuals without diabetes, it quickly became the most commonly used weight-loss medication, surpassing semaglutide ... s FDA approval for weight management. 2 Longer-term data on this ...

If approved, orforglipron would offer an alternative to another GLP-1 pill, Rybelsus (semaglutide ... data to the FDA by the end of the year for consideration of the pill for weight loss ...